Visão geral da empresa
A biopharmaceutical entity focused on the United States, Palatin Technologies, Inc. develops first-in-class medicines utilizing molecules designed to modulate the activity of the melanocortin receptor system. The company operates within the Healthcare sector, specifically the Biotechnology industry, a classification that implies a focus on high-risk, high-reward innovation often characterized by significant research and development expenditures prior to commercialization. The organization maintains a compact operational scale with a market capitalization of $35.43M, an annual revenue of $8.96M, and an employee base of 29 individuals. These specific valuation and revenue figures indicate that Palatin Technologies, Inc. functions as a small-cap biotechnology firm, suggesting it is still in a phase where market penetration or product development cycles significantly dictate its financial standing rather than established widespread revenue streams.
Saúde financeira
The company reported a trailing twelve-month revenue of $8.96M, yet recorded a net income of $-9,627,545 and an EBITDA of $-12,364,254. The substantial gap between the positive revenue of $8.96M and the significant negative net income reveals a cost structure where expenses, likely dominated by research, development, and operational costs, far exceed the income generated from sales. Furthermore, the free cash flow stands at $-12,458,299, which indicates that the company is currently burning through its cash reserves to fund its operations and development pipeline rather than generating liquidity from its core business activities. This negative cash flow position necessitates careful management of capital to ensure financial flexibility is maintained until future products achieve commercial milestones. When analyzing profitability metrics, the gross margin is -40.2%, the operating margin is -6315.8%, and the profit margin is -107.4%, all of which indicate that the company is currently operating at a significant loss across all levels of cost accounting. The company holds $14.48M in cash against $348,788 in debt, resulting in a debt-to-equity ratio of 3.04, which suggests a leveraged balance sheet where equity claims are significantly outweighed by debt obligations relative to the company's equity base. Despite the debt presence, the current ratio is 2.76, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin. Finally, the return on equity is -378.7% and the return on assets is -70.3%, metrics that reveal that management effectiveness is currently challenged by the heavy losses incurred, as the company is unable to generate positive returns on the capital invested by shareholders or the assets utilized in operations.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -8.13, a difference that implies the market is pricing in future earnings expectations that may turn positive, despite the current lack of profitability. The price-to-book ratio is 3.06, which indicates that the market values the company at a significant premium over its tangible book value, likely reflecting intangible assets such as intellectual property and the potential of its pipeline. Additionally, the price-to-sales ratio is 3.95 and the EV/EBITDA is -1.72, suggesting that traditional valuation multiples are distorted by the company's loss-making status and that investors are relying heavily on sales-based or forward-looking metrics to assess value. The 52-week high is $41.50 and the 52-week low is $2.00, placing the current trading price within a highly volatile range that reflects the speculative nature of small-cap biotechnology stocks. The beta value is -0.13, a unique metric indicating that the stock's price volatility moves inversely to the broader market or exhibits extremely low correlation with general market trends, which is uncommon and suggests idiosyncratic factors dominate its price action.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, as the company does not report positive growth rates in the traditional sense while operating at a loss. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute profits to shareholders, as there are no profits to distribute. Consequently, the company must reinvest all available earnings and cash flow, currently negative at $-12,458,299, back into its research and development efforts to advance its oral small molecule PL7737 MC4R agonist and long-acting peptide MC4R in preclinical studies. The overall growth and income profile for Palatin Technologies, Inc. is characterized by a complete absence of current income generation and traditional growth metrics, relying entirely on future potential rather than historical performance or cash distributions.